The revised EBM catalog came into force in Germany in April 2021

22

Apr 2021

The reimbursement of services in the public outpatient sector in Germany is regulated in the EBM catalogue (Einheitlicher Bewertungsmaßstab), updated once a quarter (4 times a year). The adaption time frame of the EBM catalogue for a specific code is around five years but varies depending on the evidence. The latest EBM (German Uniform Evaluation Standard) catalog came into force on April 1, 2021.

The introduced changes are mainly minor and concern adjustment of reimbursement conditions for several services (e.g., sleep-related breathing disorders management, urethral pressure profile measurement, two IVD tests) and inclusion of two new IVD tests.

The list of the most important changes in EBM for the second quarter of 2021 is presented below. The following new codes were introduced in the EBM catalog:

  • 19462 “Determination of the PIK3CA mutation status using circulating tumor DNA to indicate the targeted treatment of postmenopausal women and men with a hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative, locally advanced or metastatic breast cancer in disease progression after endocrine therapy as monotherapy, if this is mandatory according to the specialist information” with a tariff of €437.63;
  • 19463 “Targeted determination of PIK3CA mutations using circulating tumor DNA for the indication of a targeted treatment of postmenopausal women and men with a hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative, locally advanced or metastatic breast cancer in the case of progression of the disease after endocrine therapy as monotherapy, if this is mandatory according to the specialist information” with a tariff of €233.61.

Furthermore, reimbursement conditions for the following EBM codes were revised:

  • The conditions of the reimbursement of the EBM code 11601 for detection of the germline mutations of the BRCA1 and BRCA2 genes are now supplemented with the indications of adenocarcinoma of the pancreas and prostate cancer;
  • EBM code 19456 for detecting the BRCA1 and BRCA2 gene mutations in the tumor tissue is now reimbursed also for the indication of prostate cancer.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

11

May 2021

In late April and early May 2021, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, fifteen health apps are now available at the DiGA Directory.

Read more

05

May 2021

Transcatheter aortic valve implantation (TAVI/TAVR) in severe aortic stenosis treatment across all surgical risk groups was being evaluated within the "New Methods" framework since 2019. On April 26, 2021, the Decision Forum for "New Methods" made a positive coverage decision for TAVI/TAVR to treat patients with severe aortic stenosis across all surgical risk groups.

Read more

04

May 2021

In April 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0176 and 0073 with changes to be implemented not later than August 01, 2021. Four new procedure codes related to men's health and breast surgery and one new companion diagnostic code were introduced.

Read more

03

May 2021

On April 22, 2021, the List of reimbursable implants and invasive medical devices, maintained by the National Institute for Health and Disability Insurance (INAMI), was updated with the corresponding Nominative lists of brand-specific devices. Two new Nominative lists with reimbursable devices used for peripheral vascular interventions were introduced.

Read more

29

Apr 2021

On April 20, 2021, the Dutch Healthcare Institute (ZIN) published an annual report on the progress of the conditional reimbursement program. In 2020, there were 13 ongoing projects under the program, six of which concerned medical technologies. Furthermore, in 2020, percutaneous transforaminal endoscopic discectomy for the treatment of lumbosacral radicular syndrome in lumbar disc herniation was included in the basic insurance package as regular care.

Read more